scholarly journals Novel Molecular Regulators of Breast Cancer Stem Cell Plasticity and Heterogeneity

2021 ◽  
Author(s):  
Rui Zhang ◽  
Juchuanli Tu ◽  
Suling Liu
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Breast Cancer Stem Cell ◽  
Cell Plasticity ◽  
Stem Cell Plasticity

scholarly journals Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Aurélie S. Cazet ◽  
Mun N. Hui ◽  
Benjamin L. Elsworth ◽  
Sunny Z. Wu ◽  
Daniel Roden ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Cell Plasticity ◽  
Stem Cell Plasticity

scholarly journals Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer

2017 ◽  
Author(s):  
Aurélie S. Cazet ◽  
Mun N. Hui ◽  
Benjamin L. Elsworth ◽  
Sunny Z. Wu ◽  
Daniel Roden ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cancer Cell ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Stem Cell Markers ◽  
Cell Plasticity ◽  
Neoplastic Cells ◽  
Stem Cell Plasticity

ABSTRACTThe cellular and molecular basis of stromal cell recruitment, activation and crosstalk in carcinomas is poorly understood, limiting the development of targeted anti-stromal therapies. In mouse models of triple negative breast cancer (TNBC), Hh ligand produced by neoplastic cells reprogrammed cancer-associated fibroblast (CAF) gene expression, driving tumor growth and metastasis. Hh-activated CAFs upregulated expression of FGF5 and production of fibrillar collagen, leading to FGFR and FAK activation in adjacent neoplastic cells, which then acquired a stem-like, drug-resistant phenotype. Treatment with smoothened inhibitors (SMOi) reversed these phenotypes. Stromal treatment of TNBC patient-derived xenograft (PDX) models with SMOi downregulated the expression of cancer stem cell markers and sensitized tumors to docetaxel, leading to markedly improved survival and reduced metastatic burden. In the phase I clinical trial EDALINE, 3 of 12 patients with metastatic TNBC derived clinical benefit from combination therapy with the SMOi Sonidegib and docetaxel chemotherapy, with one patient experiencing a complete response. Markers of pathway activity correlated with response. These studies identify Hh signaling to CAFs as a novel mediator of cancer stem cell plasticity and an exciting new therapeutic target in TNBC.SIGNIFICANCECompared to other breast cancer subtypes, TNBCs are associated with significantly worse patient outcomes. Standard of care systemic treatment for patients with non-BRCA1/2 positive TNBC is cytotoxic chemotherapy. However, the failure of 70% of treated TNBCs to attain complete pathological response reflects the relative chemoresistance of these tumors. New therapeutic strategies are needed to improve patient survival and quality of life. Here, we provide new insights into the dynamic interactions between heterotypic cells within a tumor. Specifically, we establish the mechanisms by which CAFs define cancer cell phenotype and demonstrate that the bidirectional CAF-cancer cell crosstalk can be successfully targeted in mice and humans using anti-stromal therapy.

Regulation of Breast Cancer Stem Cell by Tissue Rigidity

2015 ◽  
Author(s):  
Jing Yang ◽  
Adam Engler ◽  
Laurent Fattet ◽  
Matthew Ondeck
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Breast Cancer Stem Cell

scholarly journals Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases

2019 ◽  
Vol 178 (2) ◽  
pp. 251-261
Author(s):  
Zhe-Bin Liu ◽  
Nader E. Ezzedine ◽  
Agda K. Eterovic ◽  
Joe E. Ensor ◽  
Helen J. Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Gene Mutations ◽  
Breast Cancer Stem Cell ◽  
Circulating Free Dna ◽  
Free Dna ◽  
Cell Gene ◽  
Stem Cell Gene

scholarly journals Breast Cancer Stem Cell Potency of Nickel(II)‐Polypyridyl Complexes Containing Non‐steroidal Anti‐inflammatory Drugs

2020 ◽  
Vol 26 (61) ◽  
pp. 14011-14017
Author(s):  
Catherine J. Feld ◽  
Alice Johnson ◽  
Zhiyin Xiao ◽  
Kogularamanan Suntharalingam
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Breast Cancer Stem Cell ◽  
Polypyridyl Complexes ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting

2021 ◽  
Vol Volume 16 ◽  
pp. 1487-1508
Author(s):  
Li Lv ◽  
Yonghui Shi ◽  
Junyan Wu ◽  
Guocheng Li
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Breast Cancer Stem Cell ◽  
Cell Targeting

Breast Cancer Stem Cell: Translating to the Clinic

2011 ◽  
pp. 249-257 ◽  
Author(s):  
Makiko Ono ◽  
Yasuhiro Fujiwara ◽  
Takahiro Ochiya
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Breast Cancer Stem Cell

scholarly journals β1 Integrin is essential for fascin‐mediated breast cancer stem cell function and disease progression

2019 ◽  
Vol 145 (3) ◽  
pp. 830-841 ◽  
Author(s):  
Rayanah Barnawi ◽  
Samiyah Al‐Khaldi ◽  
Dilek Colak ◽  
Asma Tulbah ◽  
Taher Al‐Tweigeri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Disease Progression ◽  
Cell Function ◽  
Breast Cancer Stem Cell ◽  
Β1 Integrin
Sign in / Sign up

Export Citation Format

Share Document